Nuvation Bio Completes Ibtrozi Tech Transfer to Thermo Fisher
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi - taletrectinib - to treat advanced or metastatic ROS1-positive non-small cell lung cancer, or NSCLC. The transition was submitted as a supplement to the IBTROZI New Drug Application held by Nuvation Bio and is now complete.
